Reducing donor-specific antibodies for a stem cell transplant
Treatments studied
Part of Blood & lymphatic, Cancer, Genetic & congenital, Immune system & allergy clinical trials.
This study tests a new way to reduce donor-specific antibodies before a stem cell transplant. It combines standard treatments with an increased infusion of donor cells to help improve transplant success.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a blood disease like leukemia, lymphoma, thalassemia, or aplastic anemia that needs a stem cell transplant.
- You are between 18 and 65 years old.
- Your weight is between 40 kg (about 88 lbs) and 100 kg (about 220 lbs).
- You have donor-specific antibodies (DSAs) that might cause your body to reject the donor’s stem cells.
- You do not have another suitable donor who is free of these antibodies.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests an immune-suppressing treatment for people with sickle cell disease or beta-thalassemia who are preparing for a stem cell transplant from a donor. It aims to help the transplant work better by changing the immune response.
This trial compares two reduced-intensity conditioning regimens before you receive stem cells from a donor who matches your HLA type. It aims to find which approach works better and is safer for certain blood cancers.
This trial tests a special immune-cell “preparation” treatment (called T-cell and B-cell depletion) with adjusted anti-thymocyte globulin (ATG) dosing before a stem cell transplant. It aims to reduce immune-related transplant complications in people under 25 with certain blood cancers in a specific remission status.
This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.
This trial tests a special treatment to lower high levels of anti-HLA antibodies before a stem cell transplant. The goal is to help the transplant succeed and reduce the risk of rejection.
This study tests a way to lower the chance of graft-versus-host disease (a common side effect of stem cell transplants) by removing certain immune cells from the donor's stem cells before they are given to you. It is for older patients with acute leukemia or MDS who are getting a transplant.
Hear when a new Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.